• 페이스북 공유
  • 트위터 공유
  • 미투데이 공유
  • URL복사
  • 더보기
  • 관심의료진 등록

서재홍

  • 진료과

    종양내과

  • 전문진료분야

    유방암, 비뇨기암 (암병원 3F진료)

  • 담당클리닉

    유방암 및 여성암 클리닉

  • 관련센터

    유방암센터 , 의과학연구지원센터

서재홍

서재홍 교수의 진료시간표 진료예약

진료과/센터 전문진료과목
종양내과 - - - - - - 유방암 , 비뇨기암 (암병원 3F진료)
암병원(3F)
오전
오전
-
오전
오전
- 유방암 , 비뇨기암 (항암치료)

서재홍 교수의 상세정보

학력

more
  • 1986 .03  ~  1992 .02  :  고려대학교 의과대학 의학과 학사
  • 1996 .03  ~  1998 .02  :  고려대학교 대학원 종양내과학 석사
  • 1998 .03  ~  2000 .08  :  고려대학교 대학원 종양내과학 박사

경력

more
  • 1992 .03  ~  1993 .02  :  고려대학교 의료원 수련의
  • 1993 .03  ~  1997 .02  :  고려대학교 의료원 내과 전공의
  • 1997 .03  ~  2001 .02  :  고려대학교 의료원 종양혈액내과 전임의
  • 2001 .03  ~  2002 .08  :  고려대학교 의료원 종양혈액내과 임상조교수
  • 2002 .09  ~  2005 .08  :  고려대학교 의과대학 종양내과 조교수
  • 2005 .09  ~  2011 .08  :  고려대학교 의과대학 종양내과 부교수
  • 2007 .03  ~  2009 .02  :  University of Massachusetts, Amherst, Animal Science Research Associate (Dr. Joseph D Jerry)
  • 2011 .09  ~   :  고려대학교 의과대학 종양내과 교수

수상내역

more
  • 2008  ~  2014  :  Marquis Who’s Who in the World
  • 2012  :  International Biographical Center(IBC) Top 100 Health Professional
  • 2011  ~  2012  :  American Biographical Institute Man of the Year
  • 2014  :  Leading Achiever of the World

학회활동

more
  • 1997 .01  ~   :  항암화학요법연구회 정회원
  • 1997 .01  ~   :  대한암학회 평생회원
  • 2005 .01  ~   :  대한암예방학회 정회원
  • 2006 .01  ~   :  한국임상암학회 이사
  • 2010 .01  ~   :  대한암학회 학술위원
  • 2010 .01  ~   :  대한암협회 총무위원
  • 2007 .03  ~   :  대한내과학회 평생회원
  • 2014 .03  ~   :  대한암학회 평생회원 및 이사
  • 2012 .03  ~   :  한국임상암학회 상임이사
  • 2015 .03  ~   :  한국유방암학회 회원

국내활동

more
  • 2009 .03  ~   :  고려대학교 구로병원 유방암센터장
  • 2010 .03  ~   :  고려대학교 구로병원 의과학연구소 소장
  • 2012 .11  ~  2018 .10  :  보건복지부 임상현장발굴국가핵심중개연구 “유방암표적치료제 개발연구” 주관연구 책임자(6년간 총 80억)
  • 2013 .04  ~   :  고려대학교 구로병원 연구중심병원 중점과제 책임연구자
  • 2014 .01  ~   :  고려대학교 구로병원 종양혈액내과 과장

국외활동

more
  • 2007 .03  ~  2009 .02  :  University of Massachusetts, Amherst, Animal Science Research Associate (Dr. Joseph D Jerry)

논문

more
  • [SCI] (Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer)
  • [SCI] (Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis)
  • [SCI] (Salinomycin promote anoikis and decrease the CD44+/CD24-stem-like population via inhibition of STAT3 activation in MDA-MB-231 cells)
  • [SCI] (Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway)
  • [SCI] (Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer)
  • [SCI] (YKL-40 expression could be as a poor prognostic marker in the breast cancer tissue)
  • [SCI] (A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer)
  • [SCI] (The relationship between preeclampsia, pregnancy-induced hypertension and maternal risk of breast cancer: a meta-analysis)
  • [SCI] (The relationship between Helicobacter pylori infection and the effects of chemotherapy in patients with advanced or metastatic gastric cancer)
  • [SCI] (The relationship between twin births and maternal risk of breast cancer: A meta-analysis)
  • [SCI] (Association of a vascular endothelial growth factor (VEGF) gene 936 C/T polymorphism with breast cancer risk: a meta-analysis)
  • [SCI] (A phase II study of vinorelbine monotherapy in anthracycline and taxane pretreated metastatic breast cancer)
  • [SCI] (Bevacizumab for salvage treatment of metastatic breast cancer: A systemic review and meta-analysis of randomized controlled trials)
  • [SCI] (Association of a vascular endothelial growth factor (VEGF) gene 936 C/T polymorphism with breast cancer risk: a meta-analysis)
  • [SCI] (Bevacizumab for salvage treatment of metastatic breast cancer: A systemic review and meta-analysis of randomized controlled trials)
  • [SCI] (A phase II study of vinorelbine monotherapy in anthracycline and taxane pretreated metastatic breast cancer)
  • [SCI] (Association of a TGF-β1 509 C/T polymorphism with breast cancer risk: a meta-analysis)
  • [SCI] (High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer)
  • [SCI] (Association of a progesterone receptor gene +331 G/A polymorphism with breast cancer risk: meta-analysis)
  • [SCI] (Sustained co-cultivation with human placenta-derived MSCs enhance ALK5/Smad3 signaling in human breast epithelial cells, leading to EMT and differentiation)
  • [SCI] (Docetaxel and epirubicin salvage regimen in anthracycline sensitive metastatic breast cancer patients relapsed after anthracycline-containing adjuvant therapy)
  • [국외논문] (Amniotic membrane might be applied to cancer treatment)
  • [국외논문] (PPAR-γ ligand promote the growth of APC mutated colon cancer cell in vitro and in vivo)
  • [국외논문] (Extrinsic NO donor partially reverse Arginine Deiminase (ADI) induced anti-proliferative activity through NFB and Bcl-XL)
  • [국외논문] (Functional implication of Akt Activity and TGF-? signaling in Tamoxifen-resistanct Breast Cancer)
  • [국외논문] (Meta-analysis of pre-operative aromatase inhibitor versustamoxifen in postmenopausal woman with hormone receptor-positive breast cancer)
  • (Phase II study of a Gemcitabine and Cisplatin combination regimen in taxane resistant metastatic breast cancer)
  • [국외논문] (Epirubicin, Cisplatin, Oral UFT and Leucovorin Combination Chemotherapy in Advanced and Metastatic Esophageal Cancer)
  • [국외논문] (uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in MDA-MB-231 breast carcinoma cell line)
  • [국외논문] (Autocrine VEGF/VEGF Receptor-2 Growth Pathway Represents a Cyclooxygenase-2-Independent Target for Cycooxygenase-2 Inhibitor NS-398 in Colon Cancer Cells)

최종수정일 : 2019.02.28